Effect of Neoadjuvant Immunotherapy Combined with Chemotherapy on Pulmonary Function and Postoperative Pulmonary Complications in Esophageal Cancer: A Retrospective Study

Author:

Gao Yongyin1,Zhang Hongdian2,Qiu Yanli1,Bian Xueyan1,Wang Xue1,Li Yue1

Affiliation:

1. Department of Cardio-pulmonary Functions, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

2. Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Abstract

Background: Neoadjuvant immunotherapy, targeting the PD-1 or PD-L1, combined with chemotherapy (NICT), can improve the radical resection and survival rates for locally advanced EC. However, it may impair pulmonary function, and the effect of NICT on pulmonary function and postoperative pulmonary complications in EC patients remains unknown. This study aimed to investigate whether NICT can affect pulmonary functions and postoperative pulmonary complications in EC patients. Methods: The study retrospectively recruited 220 EC patients who received NICT at the Department of Esophageal Cancer in Tianjin Medical University Cancer Institute & Hospital from January 2021 to June 2022. Changes in pulmonary function before and after NICT were compared. Logistic regression analysis was performed to analyze the correlations of pulmonary functions and clinical characteristics with postoperative pulmonary complications, respectively. Results: The FEV1% pred, FVC, FVC% pred, and FEV1/FVC% significantly increased after NICT, with a P-value of 0.018, 0.005, 0.001, and 0.036, respectively. In contrast, there was a significant decline in the DLCO (8.92 ± 2.34 L before NICT vs. 7.79 ± 2.30 L after NICT; P < 0.05) and DLCO% pred (102.97 ± 26.22% before NICT vs. 90.18 ± 25.04% after NICT; P < 0.05). High DLCO and DLCO% pred at baseline levels were risk factors for DLCO reduction in EC patients after NICT. Advanced age, smoking history, FEV1% pred after NICT, and FVC% pred baseline and after therapy were risk factors for postoperative pulmonary complications, with a P-value of 0.043, 0.038, 0.048, 0.034, and 0.004, respectively. Although the DLCO level decreased after NICT, it did not increase the incidence of postoperative pulmonary complications. Conclusion: NICT may improve pulmonary ventilation function but also lead to a decrease in DLCO and DLCO% pred in EC patients. Nevertheless, the decreased DLCO after NICT did not increase the risk of postoperative pulmonary complications.

Publisher

Bentham Science Publishers Ltd.

Reference36 articles.

1. He F.; Wang J.; Liu L.; Qin X.; Wan Z.; Li W.; Ping Z.; Esophageal cancer: Trends in incidence and mortality in China from 2005 to 2015. Cancer Med 2021,10(5),1839-1847

2. van Hagen P.; Hulshof M.C.C.M.; van Lanschot J.J.B.; Steyerberg E.W.; Henegouwen M.I.B.; Wijnhoven B.P.L.; Richel D.J.; Nieuwenhuijzen G.A.P.; Hospers G.A.P.; Bonenkamp J.J.; Cuesta M.A.; Blaisse R.J.B.; Busch O.R.C.; ten Kate F.J.W.; Creemers G.J.; Punt C.J.A.; Plukker J.T.M.; Verheul H.M.W.; Bilgen E.J.S.; van Dekken H.; van der Sangen M.J.C.; Rozema T.; Biermann K.; Beukema J.C.; Piet A.H.M.; van Rij C.M.; Reinders J.G.; Tilanus H.W.; van der Gaast A.; Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012,366(22),2074-2084

3. Chan K.K.W.; Saluja R.; Delos Santos K.; Lien K.; Shah K.; Cramarossa G.; Zhu X.; Wong R.K.S.; Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. Int J Cancer 2018,143(2),430-437

4. Rittmeyer A.; Barlesi F.; Waterkamp D.; Park K.; Ciardiello F.; von Pawel J.; Gadgeel S.M.; Hida T.; Kowalski D.M.; Dols M.C.; Cortinovis D.L.; Leach J.; Polikoff J.; Barrios C.; Kabbinavar F.; Frontera O.A.; De Marinis F.; Turna H.; Lee J.S.; Ballinger M.; Kowanetz M.; He P.; Chen D.S.; Sandler A.; Gandara D.R.; Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 2017,389(10066),255-265

5. Smyth E.C.; Gambardella V.; Cervantes A.; Fleitas T.; Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol 2021,32(5),590-599

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3